- Home
- AZ vs CLLS Comparison
AZ vs CLLS Comparison
Compare AZ & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZ
- CLLS
- Stock Information
- Founded
- AZ 2018
- CLLS 1999
- Country
- AZ Canada
- CLLS France
- Employees
- AZ N/A
- CLLS N/A
- Industry
- AZ Industrial Machinery/Components
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- AZ Industrials
- CLLS Health Care
- Exchange
- AZ Nasdaq
- CLLS Nasdaq
- Market Cap
- AZ 319.5M
- CLLS 299.0M
- IPO Year
- AZ N/A
- CLLS 2007
- Fundamental
- Price
- AZ $7.47
- CLLS $4.30
- Analyst Decision
- AZ Strong Buy
- CLLS Buy
- Analyst Count
- AZ 1
- CLLS 1
- Target Price
- AZ $20.00
- CLLS $4.00
- AVG Volume (30 Days)
- AZ 441.9K
- CLLS 161.1K
- Earning Date
- AZ 11-12-2025
- CLLS 11-03-2025
- Dividend Yield
- AZ N/A
- CLLS N/A
- EPS Growth
- AZ N/A
- CLLS N/A
- EPS
- AZ N/A
- CLLS N/A
- Revenue
- AZ $7,489,000.00
- CLLS $63,438,000.00
- Revenue This Year
- AZ $1,343,857.60
- CLLS N/A
- Revenue Next Year
- AZ N/A
- CLLS $66.76
- P/E Ratio
- AZ N/A
- CLLS N/A
- Revenue Growth
- AZ 19.04
- CLLS 223.09
- 52 Week Low
- AZ $1.76
- CLLS $1.10
- 52 Week High
- AZ $12.36
- CLLS $4.53
- Technical
- Relative Strength Index (RSI)
- AZ 35.94
- CLLS 74.29
- Support Level
- AZ $7.35
- CLLS $3.36
- Resistance Level
- AZ $7.93
- CLLS $3.60
- Average True Range (ATR)
- AZ 0.50
- CLLS 0.24
- MACD
- AZ -0.03
- CLLS 0.08
- Stochastic Oscillator
- AZ 10.57
- CLLS 96.51
About AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.